Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12972229 | 0.81 | — | — | |
| SCHEMBL3293554 | 0.79 | IKBKE (0.32) | ALDH1A1 | |
| SCHEMBL30984508 | 0.77 | — | — | |
| SCHEMBL1187089 | 0.74 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL13325881 | 0.74 | CALM1 (0.34) | ALDH1A1 | |
| SCHEMBL12556815 | 0.74 | — | — | |
| SCHEMBL17471333 | 0.73 | TBK1 (0.40) | ALDH1A1SUV39H2 | |
| SCHEMBL3396841 | 0.72 | CES2 (0.31) | ALOX15CYP1B1ALDH1A1 | |
| Boric Acid SCHEMBL22284324 | 0.72 | — | — | |
| SCHEMBL11801837 | 0.71 | PKM (0.33) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024125488-A1 | AROMATIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 浙江海正药业股份有限公司 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024015346-A1 | CEREBLON LIGANDS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. d.b.a PROTEOVANT THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-3774755-B1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | PHENEX DISCOVERY VERWALTUNGS GMBH (DE) | 2022-05-18 | — | — | EP | disclosed |
| EP-3774755-B1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | PHENEX DISCOVERY VERWALTUNGS GMBH (DE) | 2022-05-18 | — | — | EP | disclosed |
| US-11203592-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203592-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210221806-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-07-22 | — | — | US | disclosed |
| US-20210221806-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-07-22 | — | — | US | disclosed |
| US-20210122757-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2021-04-29 | — | — | US | disclosed |
| US-20210122757-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2021-04-29 | — | — | US | disclosed |
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |
| WO-2014009222-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | BASILEA PHARMACEUTICA AG (CH) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| US-20130317001-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2013-11-28 | — | — | US | disclosed |
| WO-2013177224-A1 | N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN | GENENTECH, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-5972979-A | Tricyclic spiro compounds as 5HT1D receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-10-26 | — | — | US | disclosed |
| EP-0862565-A1 | TRICYCLIC SPIRO COMPOUNDS AS 5HT 1D? RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997019070-A1 | TRICYCLIC SPIRO COMPOUNDS AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122757-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | ALOX15 957/4885CYP1B1 170/4885ALDH1A1 327/4885 |
| US-20130317001-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SNRPD2 | ALOX15 3896/4885CYP1B1 89/4885ALDH1A1 2216/4885 |
| US-11203592-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | ALOX15 366/4885CYP1B1 239/4885ALDH1A1 373/4885 |
| US-20210221806-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | ALOX15 366/4885CYP1B1 239/4885ALDH1A1 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.